Aeglea BioTherapeutics, Inc. (AGLE)
Company Info
| ISIN | US00773J1034 |
|---|---|
| CUSIP | 00773J103 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $48.63M |
|---|---|
| EPS (TTM) | -$74.15 |
| PE Ratio | 11.17 |
| EBITDA (TTM) | -$18.34M |
| Year Range | $8.43 - $28.66 |
| Target Price | $17.50 |
| Short % | 3.47% |
| Short Ratio | 3.68 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Aeglea BioTherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | N/A | 13.20% |
| 1 month | N/A | -1.28% |
| 6 months | N/A | 10.32% |
| 1 year | N/A | 18.23% |
| 5 years (annualized) | N/A | 12.31% |
| 10 years (annualized) | N/A | 10.58% |
Monthly Returns
The table below presents the monthly returns of AGLE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | 11.14% | -21.60% | -26.02% | -41.83% | -23.00% | 246.81% | 25.44% | 1.75% | -14.78% | -4.98% | 60.31% | 15.33% | 91.33% |
| 2022 | -9.47% | -35.58% | -16.97% | -37.39% | 9.72% | -68.03% | -17.76% | 25.90% | 0.57% | 95.82% | -59.71% | 8.41% | -90.53% |
| 2021 | -11.69% | 7.19% | 6.31% | -1.77% | -15.04% | 5.30% | -11.93% | 18.27% | 9.66% | -7.92% | -14.75% | -23.88% | -39.64% |
| 2020 | -4.97% | -5.92% | -31.77% | 66.74% | 13.38% | 4.99% | -25.95% | 6.20% | -2.54% | 8.32% | 11.46% | -8.06% | 3.01% |
| 2019 | 22.03% | -8.53% | -3.71% | -14.91% | -8.91% | 9.78% | 30.80% | -12.89% | -1.47% | -1.04% | 12.35% | -10.64% | 2.00% |
| 2018 | 19.78% | 11.88% | 36.83% | -5.85% | 14.35% | -0.94% | -20.51% | 29.96% | -12.44% | -9.82% | -2.43% | -11.05% | 38.45% |
| 2017 | -8.28% | 55.39% | 20.16% | -4.03% | -40.98% | -8.77% | -11.43% | 20.53% | 19.94% | -11.15% | -8.68% | 35.25% | 24.37% |
| 2016 | -10.34% | -14.38% | -35.20% | -1.23% | 17.50% | 13.65% | -16.38% | -3.54% | -15.86% | -55.48% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Aeglea BioTherapeutics, Inc. (AGLE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Aeglea BioTherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aeglea BioTherapeutics, Inc. was 99.11%, occurring on Jun 21, 2023. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.11% | Apr 11, 2016 | 1812 | Jun 21, 2023 | — | — | — |
Volatility
Volatility Chart
The current Aeglea BioTherapeutics, Inc. volatility is 23.43%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Aeglea BioTherapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |